Scholar Rock stock: TD Cowen keeps USD 71.00 target for Scholar Rock stock
Published on 10/24/2026 at 04:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSEuropean filing and launch timeline
- TD Cowen maintained a USD 71.00 target on October 21, 2026.
- Scholar Rock resubmitted its European application on October 8, 2026, with a CHMP opinion expected in the first half of 2027.
- Scholar Rock reported a USD 109.9 million GAAP net loss for the second quarter of 2026.
Scholar Rock (ISIN US80706P1030) resubmitted its European marketing application for apitegromab on October 8, 2026, according to StockTitan. The company expects a CHMP opinion in the first half of 2027, making the European regulatory path the next major milestone for its SMA treatment.
What does the filing mean for Europe?
The resubmission uses an alternate fill-finish facility after the earlier application was withdrawn over manufacturing compliance issues. The same facility supported the September 11, 2026, US approval of ISEMBYLD, according to StockTitan. The release said vials were already at a third-party provider and awaiting packaging and labeling, subject to European Commission approval.
Three dated Scholar Rock milestones
On September 11, 2026, the FDA approved ISEMBYLD for adults and children at least 2 years old receiving an SMN2-targeted treatment. On October 8, 2026, Scholar Rock resubmitted the European application and cited the alternate facility. On October 20, 2026, the company announced that it would report third-quarter 2026 results on November 10, 2026, according to BioSpace.
What are analysts targeting?
TD Cowen analyst Ritu Baral maintained a Buy rating and set a USD 71.00 price target on October 21, 2026, as reported by Markets Insider. Truist Financial reiterated a Buy rating with a USD 77.00 target on October 20, 2026, according to Markets Insider. The valuation case remains tied to the commercial launch of ISEMBYLD and progress toward European approval.
When are the next results?
Scholar Rock will report third-quarter 2026 financial results on November 10, 2026, before the US market opens, with a conference call scheduled for 8:00 a.m. ET. For context, the company reported a USD 109.9 million GAAP net loss for the second quarter of 2026 and held USD 437.1 million in cash on June 30, 2026.
European approval remains the next test
Scholar Rock's market capitalization was USD 5.1 billion as of October 23, 2026, while its 52-week range was USD 27.07 to USD 61.76. The November results will offer the next dated checkpoint for the US launch and the company's cash position.
The further course of trading is shown by the continuously updated real-time quote of Scholar Rock stock.
Scholar Rock stock key data
- Company: Scholar Rock Holding Corporation
- ISIN: US80706P1030
- Ticker: SRRK
- Primary exchange: Nasdaq
- Market capitalization: USD 5.1 billion (as of October 23, 2026)
- 52-week range: USD 27.07-61.76 (as of October 23, 2026)
- Sector / Industry: Healthcare / Biotechnology
Market context: Market report S&P 500.
